根治性前列腺切除术中的盆腔淋巴结清扫用于中危前列腺癌:在全州质量改进联盟内评估效用与淋巴结转移
基于密歇根泌尿外科手术改进协作组的前瞻性数据,分析8591例中危前列腺癌患者行机器人辅助根治性前列腺切除术时的盆腔淋巴结清扫(PLND)情况与淋巴结阳性(LN+)率。结果显示80.2%接受了PLND,其中2.9%为LN+;有利中危与不利中危的LN+率分别为1.2%与4.7%。数据支持对所有不利中危患者行PLND,有利中危中LN+风险较高者为≥50%穿刺针阳性、任一针≥35%受累和/或不利基因组分类结果。
要点
- 8591例中危前列腺癌行机器人辅助根治性前列腺切除术,80.2%同时行盆腔淋巴结清扫。
- 淋巴结阳性率总体2.9%;有利中危1.2%,不利中危4.7%。
- 有利中危中LN+风险较高者为≥50%穿刺针阳性、任一针≥35%受累和/或不利基因组分类结果。
核心结论
- 数据支持对所有不利中危前列腺癌患者在机器人辅助根治性前列腺切除术时行盆腔淋巴结清扫。
- 有利中危患者中LN+风险最高者为≥50%穿刺针阳性、任一针≥35%受累和/或不利基因组分类结果者。
研究设计与样本
- 前瞻性收集2012年3月至2020年10月所有机器人辅助根治性前列腺切除术的数据,包括患者与术者特征。
- 对盆腔淋巴结清扫率与淋巴结受累(LN+)行单变量和多变量分析。
- 共纳入8591例中危前列腺癌患者。
主要发现
- 8591例中危前列腺癌患者中,80.2%(n=6883)行盆腔淋巴结清扫,其中2.9%(n=198)为LN+。
- 按当前AUA风险分层,有利中危LN+率为1.2%,不利中危为4.7%。
- 有利中危亚组的LN+率为0.0%-1.3%,不利中危亚组为3.5%-5.0%。
- 与较高LN+率相关的其他因素包括≥50%穿刺针阳性、任一针≥35%受累和不利基因组分类结果,这些因素均不贡献于有利/不利亚组划分。
关键数值与推荐
- AUA指南:不利中危和高危局限期前列腺癌推荐行盆腔淋巴结清扫,有利中危可考虑。
- NCCN指南:淋巴结转移风险≥2%时推荐行盆腔淋巴结清扫。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess which patients with intermediate-risk PCa would benefit from a pelvic lymph node dissection (PLND) across the Michigan Urological Surgery Improvement Collaborative, given the discrepancy in recommendations. AUA guidelines for localized prostate cancer (PCa) state that PLND is indicated for patients with unfavorable intermediate-risk and high-risk PCa and can be considered in favorable intermediate-risk patients. NCCN guidelines recommend PLND when risk for nodal disease is ≥2%. METHODS: Data regarding all robot-assisted radical prostatectomy (RARP) (March 2012-October 2020) were prospectively collected, including patient, and surgeon characteristics. Univariate and multivariate analyses of PLND rate and lymph node involvement (LN+) were performed. RESULTS: Among 8,591 men undergoing RARP for intermediate-risk PCa, 80.2% were performed with PLND (n = 6883), of which 2.9% were LN+ (n = 198). According to the current AUA risk stratification system, 1.2% of favorable intermediate-risk PCa and 4.7% of unfavorable intermediate-risk PCa demonstrated LN+. There were also differences in the LN+ rates among the subgroups of favorable (0.0%-1.3%), and unfavorable (3.5%-5.0%) categories. Additional factors associated with higher LN+ rates include ≥50% cores positive, ≥35% involvement at any core, and unfavorable genomic classifier result, none of which contribute to the favorable/unfavorable subgroups. CONCLUSION: These data support PLND at RARP for all patients with unfavorable intermediate-risk PCa. Our data also indicate patients with favorable intermediate-risk prostate cancer at greatest risk for LN+ are those with ≥50% cores positive, ≥35% involvement at any core, and/or unfavorable genomic classifier result.
引用
- Kuperus JM, Tobert CM, Semerjian AM, et al. Pelvic Lymph Node Dissection at Radical Prostatectomy for Intermediate Risk Prostate Cancer: Assessing Utility and Nodal Metastases Within a Statewide Quality Improvement Consortium. Urology. 2022. PMID: 35263639. doi:10.1016/j.urology.2022.01.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。